ELUTIA INC
ELUTNASDAQTrading Snapshot
- Day Range
- $858.67 – $883.28
- 52-Week Range
- —
- Volume
- $4.24B
- Avg Volume
- $4.93B
- Shares Outstanding
- —
- Next Earnings
- Oct 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $72.08B
- Last Q Revenue
- $18.72B
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own ELUT
- ✓High-growth profile — revenue up +27.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 62% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ELUTIA INC
A company profile for ELUTIA INC isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Price Target
ⓘLatest News & Updates
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Advanced Biomed (NASDAQ:ADVB) shares rose 24.1% to $6.24 during Monday's pre-market session. The market value of their outstanding shares is at $8.2 million. Barinthus Biotherapeutics (NASDAQ:BRNS) shares
Elutia Sheds Legacy Business to Chase $1.5 Billion Market Opportunity
Elutia (NASDAQ:ELUT) sells SimpliDerm to Cellution Biologics for up to $11M to boost its balance sheet ahead of the NXT-41x launch.
Cellution Biologics Inc. Signs Definitive Agreement to Acquire SimpliDerm® Human Hydrated Acellular Dermal Matrix Business from Elutia Inc., Expanding its Allograft Portfolio
Acquisition marks Cellution Biologics' entry into the U.S. reconstructive surgery market through an established human acellular dermal matrix platform.SimpliDerm® expands Cellution Biologics' advanced biologics portfolio beyond wound care, ocular repair, and other surgical applications into reconstructive surgery.Transaction supports Cellution Biologics' long-term strategy of building a global biologics platform while ensuring continuity of supply for existing customers. ROSWELL, Ga., July 16, 2
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
Transaction provides $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 monthsProceeds provide additional non-dilutive capital to advance NXT-41x toward anticipated clearance and targeted commercial launch in 2027Divestiture sharpens Elutia’s focus on NXT-41x and the $1.5 billion plastic and reconstructive surgery opportunity GAITHERSBURG, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “